Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2020 | HER2CLIMB-02: tucatinib + TDM-1 in advanced breast cancer

Sara Hurvitz, MD, Ronald Reagan UCLA Medical Center, Los Angeles, CA, discusses the HER2CLIMB-02 trial (NCT02614794), whose aim was to assess the safety and efficacy of a combined tucatinib and TDM-1 therapy in previously treated HER2-positive metastatic breast cancer patients. When added to TDM-1, tucatinib, a tyrosine kinase inhibitor, showed improved response rates, particularly in patients with a history of CNS metastasis. Encouraging progression-free survival (PFS) and overall survival (OS) rates were also observed. At the San Antonio Breast Cancer Symposium (SABCS) 2020, Dr Hurvitz discusses the ongoing, Phase III HER2CLIMB-02 study (NCT03975647) evaluating tucatinib vs. placebo in combination with T-DM1 in patients with advanced or metastatic HER2+ breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.